Arcturus Therapeutics Q2 2024 GAAP EPS $(0.64) Beats $(1.62) Estimate, Sales $49.859M Beat $21.696M Estimate
Portfolio Pulse from Benzinga Newsdesk
Arcturus Therapeutics (NASDAQ:ARCT) reported Q2 2024 GAAP EPS of $(0.64), beating the estimate of $(1.62). Sales were $49.859M, surpassing the $21.696M estimate and showing a 373.99% increase from the same period last year.
August 05, 2024 | 8:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arcturus Therapeutics reported better-than-expected Q2 2024 earnings and sales, with EPS of $(0.64) beating the $(1.62) estimate and sales of $49.859M surpassing the $21.696M estimate. This represents a significant 373.99% increase in sales from the same period last year.
The significant beat on both EPS and sales estimates, along with a substantial year-over-year increase in sales, is likely to positively impact ARCT's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100